Medigen Vaccine Biologics Corporation (TPEX: 6547)
Health Care · Biotechnology · TW
NT$55.70
+8.16% today · +43.2% 1Y
Medigen Vaccine Biologics Corporation (TPEX: 6547) operates in the Biotechnology industry within the Health Care sector. The company is valued at $575.05M and employs 1,226 people.
Over the last twelve months the share price has gained 43.2%, trading between 33.50 and 61.20.
Tweenvest scores Medigen Vaccine Biologics Corporation across four factors: quality 60/100, value 62/100, growth 60/100. Its strongest factor is value.
6547 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $575.05M
- Revenue (TTM)
- $18.04M
- P/E
- —
- EPS
- -0.53
- Dividend yield
- —
- Beta (5Y)
- -0.06
- 52-week high
- NT$61.20
- 52-week low
- NT$33.50
- Avg volume (3M)
- —
- Shares outstanding
- 328.75M
- Employees
- 1,226
- Next earnings
- —
About Medigen Vaccine Biologics Corporation
Medigen Vaccine Biologics Corporation, a biotechnology drug company, engages in the research, development, and wholesale of vaccines and biopharmaceuticals, and medical devices in Taiwan. It develops enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection with severe complications; and Quadrivalent influenza vaccine, which is in Phase III clinical trial for the treatment of influenza viruses. The company also develops dengue vaccines, which has completed Phase II clinical trial to treat dengue; anti respiratory syncytial virus (RSV), which is in Phase I clinical trial for the prevention of RSV infection; and COVID-19 vaccine, which is in Phase III clinical trial to prevent COVID-19. The company was incorporated in 2012 and is headquartered in Zhubei, Taiwan. Medigen Vaccine Biologics Corporation operates as a subsidiary of Medigen Biotechnology Corp.
- ISIN
- TW0006547003
- Founded
- 2012
- Listed since
- Sep 16, 2015
- Exchange
- Taipei Exchange
- Currency
- TWD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $443.84 | +1.03% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $63.06B | €875.40 | +1.30% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $141.70 | +2.02% |
Figures last refreshed Aug 18, 2026.